Target RWE Shares Weight Loss Data From Ongoing NASH Study
Real-world study shows only 32% of overweight or obese adults with NAFLD in the U.S. achieved 5% or more weight reduction
News provided by
Share this article
DURHAM, N.C., Feb. 2, 2021 /PRNewswire/ --
Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, shared the latest data from the ongoing TARGET-NASH observational study, published in
The nonalcoholic steatohepatitis (NASH) study,
Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort, analyzed 2,019 patients enrolled in the TARGET-NASH cohort in the United States over a median follow-up of 39 months. The baseline characteristics included one third of patients classified as obesity class 2/3, 38.6% of patients had diabetes, and approximately 50% had documentation of lifestyle modifications or diet recommendations.